Trial
NCT03067571
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
High Risk Myelodysplastic Syndrome
Intervention
Daratumumab
Why stopped
Study terminated early because of lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-21